Drugs / Renogen
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT03286712 | Oct 2015 → Mar 2017 | anemia, chronic kidney disease, peritonitis | National Kidney and Transplant Institute, Philippines | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Renogen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03286712 ↗ |
| Route | Subcutaneous | “Patients will be required to follow-up at least twice a month for 3 months to give the 2 week supply of erythropoietin alpha (Renogen), administration of subcutaneous drug” NCT03286712 ↗ |